



## ASX ANNOUNCEMENT

23 April 2026

### Vitrafy Life Sciences – Q3 FY26 Investor Briefing

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) will release its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2026 on Tuesday, 28 April 2026.

Vitrafy will host an investor briefing at **9.30am (AEST) on Tuesday, 28 April 2026** to present the results.

The Company invites investors to join the briefing. To attend, please register via the following link:  
[https://us06web.zoom.us/meeting/register/IG\\_b4Y0XTLihX5c5yGe3xQ](https://us06web.zoom.us/meeting/register/IG_b4Y0XTLihX5c5yGe3xQ)

After registering, you will receive a confirmation email containing information on how to join the briefing.

Investors are encouraged to submit any questions in advance to Vitrafy's Investor Relations using the contact details below.

**### ENDS ###**

This announcement is authorised by the Company Secretary of Vitrafy Life Sciences Limited.

#### **For further information contact:**

##### **Investor and Media Relations**

Simon Martin

Chief Financial Officer

[investors@vitrafy.com](mailto:investors@vitrafy.com)

##### **About Vitrafy Life Sciences Limited**

Vitrafy Life Sciences Limited (ASX: VFY) has developed breakthrough cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain™ software platform, and Smart Packaging systems.

For more information visit [vitrafy.com](http://vitrafy.com).